A Heavy Burden: Obesity and Diabetes" Diabetes In and Out University of Rochester School of Medicine and Dentistry March 12, 2016
|
|
|
- Kimberly Holmes
- 6 years ago
- Views:
Transcription
1 A Heavy Burden: Obesity and Diabetes" Diabetes In and Out University of Rochester School of Medicine and Dentistry March 12, 2016 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics Charles A. Boettcher II Chair in Atherosclerosis University of Colorado Anschutz Medical Campus
2 Duality of Interests Consultant/Advisory Boards ISIS Pharmaceuticals Merck Novo Nordisk Regeneron/Sanofi Grants/Research Fellowships ISIS Pharmaceuticals UniQure Medical Education CMHC Medscape Medical Education Resources MedIntelligence VOX Media
3 Objectives Discuss the etiologies of obesity and the science behind the defense of body weight (fat). Review the therapeutic options for treating obesity in patients with type 2 diabetes.
4 Pathogenic Factors in Obesity Genes Monogenic Polygenic Pathway Adjustment Development Postnatal factors Epigenetic Environment Food availability Diet composition Physical activity Drugs Psychology Behavior patterns Depression Culture
5 Genetic Determinants of T2DM and Obesity Rare Monogenic (<1%) 15% MODY (1-5%) Common Gene Variants 5% T2DM Additional variants with smaller effects? Less frequent variants with larger effects? Untranscribed DNA? Micro RNAs? Gene-gene interactions? Gene-environment interactions? Epigenetic effects? Obesity
6 Only hypothesis generating
7 Prevention of Weight Gain It s all a matter of energy balance! In the absence of edematous disorders, if you re burning less than you re eating you gain weight E Out < E In WT
8 Obesity Incidence Based on Energy Balance Calculations BMI 25.0 kg/m 2, Ht - 68, Wt 164 lb vs. BMI 30.0 kg/m 2, Ht 68, Wt 197 lb over 25 years is 10 kcal/day excess
9 Body Weight Regulation SET OR SETTLING POINT?
10 Schematic Representation of the Natural History of Obesity Body Weight prevention therapeutic space years months years Time Eckel RH, Kahn S et al: Diabetes Care 34:1424; JCEM 96:1654, 2011
11 Multiple Hormonal Signals Influence Food Intake Hormonal signals Leptin Adiponectin GLP-1 Ghrelin PYY CCK Amylin Insulin Organ Adipose Tissue Gut Pancreas
12 Once obesity occurs, body fat is defended!
13 Long-Term Follow-Up of Behavioral Treatment for Obesity Kramer, F.M. et al, Int J Obes 13:131, 1989
14 Preservation of Weight Loss by Different Interventions Svetkey LP t al, JAMA 299:1139, 2008
15 The Biology of Reduced Obesity leptin, ghrelin, GLP-1 appetite preference for energy dense foods insulin sensitivity adipose tissue TG lipolysis pro-inflammatory cytokines adipose tissue lipoprotein lipase skeletal muscle lipoprotein lipase CHO oxidation & fat storage physical activity Eckel RH, NEJM, 358:18, 2008
16 How much change in AT mass is needed to be defended? Let s ask this question in walkingwell normal weight women.
17 Total Body % Fat Changes: DXA Change from Baseline (%) Control Lipectomy 6 wk 12 mo
18 Hernandez TL et al, Obesity 19:1388, 2011 Change in Trunk Fat (DEXA) in Normal Weight Women after Suction Lipectomy Changes from Baseline (%) Control Lipectomy 6 wk 12 mo
19 So even in walking-well normal weight women, total body fat is defended one year after suction lipectomy - and perhaps in less favorable locations! Hernandez TL et al, Obesity 19: , 2011
20 The Complex Biology of Weight Regain after Weight Loss MacLean PS et al, Obesity Rev Suppl 1: 45, 2015
21
22 Predictors of Weight Loss Maintenance: NWCR Energy Intake avoid frying substitute low-fat for high-fat Leisure Time Exercise # of strenuous activities/wk # of sweat episodes/wk Restraint Scale Concern about dieting Weight fluctuation McGuire, M.T. et al, Obesity Res 7:334, 1999
23 Pharmacotherapy for Reduced- Obesity Maintenance Appetite typically increases after successful weight reduction, a predictor or weight regain. All pharmacological agents except orlistat used in obesity treatment work by reducing appetite and decreasing food intake. Anti-obesity drugs have been associated with improved weight-loss maintenance after 12 kg of weight reduction. Johansson K et al, AJCN, 99:14, 2014
24 Weight Loss Maintenance in 20 Randomized Controlled Trials Johansson K et al, AJCN, 99:14, 2014
25 Progression to Type 2 Diabetes from normal Diagnosis Insulin Secretion Insulin Resistance At the time of diagnosis, ~50% of insulin secretory capacity has been lossed. Prandial defect occurs first. Postprandial Glucose Fasting Glucose Years From Diagnosis Ramlo-Halsted BA and Edelman SV. Prim Care 26:771, 1999; Nathan DM. NEJM 347:1342, 2002
26 Approaches to Weight Loss in Patients with Type 2 Diabetes
27 Weight Effects of Glucose-Lowering Medications Medication class GLP-1 analogs Metformin Bromocryptine SGLT2 inhibitors Weight effects ± or α-glucosidase inhibitors ± DPP-4 inhibitors ± Insulin Sulfonylureas Glinides Thiazolidinediones Eckel RH et al. Diabetes Care 34: ; 2011
28 Approaches to Weight Loss in Patients with Type 2 Diabetes Lifestyle Behavioral modification Medications Metabolic surgery
29 Weight Loss in T2DM and Less CVD: Did Look AHEAD Answer All the Questions? Primary Objective To assess the long-term (11.5 yr) effects of an intensive weight loss program over 4 years in overweight and obese subjects with type 2 diabetes. n = 5145 men and women in 16 study centers Weight loss vs. support and education age: yr BMI > 25 kg/m2 Primary outcome time to a major CVD event Secondary outcomes many Study stopped early for no benefit on primary outcome Look AHEAD Study Group, NEJM 369:145, 2013
30 Look AHEAD: Weight Change Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
31 Look AHEAD: Glycated Hb Change Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
32 Look AHEAD: Change in BP Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
33 Look AHEAD: Change in HDL-C Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
34 Look AHEAD: Change in TG Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
35 Look AHEAD: Change in LDL-C Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
36 Look AHEAD: Change in Rx Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
37 Look AHEAD: Primary MACE Outcome Intervention Control Look AHEAD Study Group, NEJM 369:145, 2013
38
39 Why Did Look AHEAD Fail? Insufficient power? In particular subgroups No CVD history? More weight loss and maintenance was needed? But what about dietary composition (<30% fat)? Educational sessions in Control group? Statin drop-in in the Control group? Patients in both groups were reasonably well managed for CVD risk?
40 Greater Weight Loss Further Reduces the Incidence of New-Onset Diabetes Diabetes Prevention Program Incidence rate per 100 person-years Change in weight from baseline (kg) =Overall risk at the mean weight loss* Hamman RF, et al. Diabetes Care 29:2102, 2007
41 Genetic Risk vs. Lifestyle in T2DM? (TCF7L2 SNP) Lifestyle intervention trumps genetic risk Florez J et al, DPP Research Group, NEJM 355:241, 2006
42 The New Options FDA approved drugs within the last 4 years Phentermine/Topiramate ER Lorcaserin Naltrexone/bupropion Liraglutide
43 Neuron Populations in the ARC Two neuron populations with opposing effects on food intake In the hypothalamic arcuate nucleus (ARC): Stimulate food intake NPY (neuropeptide Y) AgRP (agouti-related peptide) Suppress food intake POMC (proopiomelanocortin) CART (cocaine- and amphetamine-regulated transcript)
44 Phentermine/Topiramate ER Mechanism of Action Phentermine Sympathomimetic amine - NE release
45 Phentermine Increases Norepinephrine Release????
46 Phentermine/Topiramate ER: Mechanism of Action Phentermine Sympathomimetic amine - NE release Topiramate GABA activity AMPA/kainate glutamate receptor carbonic anhydrase
47 Topiramate Action on GABAergic Neurons Topiramate
48 Phentermine/Topiramate ER Prevents Progression to T2DM: SEQUEL Annualized Incidence of T2DM 54% P= % P < 0.01 Garvey WT, et al. AJCN 95:297, 2012
49 Effects of Phentermine/Topiramate ER in Patients with T2DM: SEQUEL A1C (%) LS Mean A1C (%) Change in A1C Placebo (n=55) Phen/TPM ER 7.5/46 mg (n=26) Phen/TPM ER 15/92 mg (n=64) * P=0.013 for between-group differences. Patients With Net Change* in Diabetes Medications (%) Change in Diabetes Medications Placebo (n=227) Phen/TPM ER 7.5/46 mg (n=153) Phen/TPM ER15/92 mg (n=295) Garvey WT, et al. AJCN 95:297, 2012
50 Lorcaserein: Mechanism of Action Selective 5-HT receptor 2C agonist POMC α-msh food intake
51
52 Lorcaserin Dose in Obese Patients with Type 2 Diabetes Mellitus: BLOOM-DM Lorcaserin 10 mg BID Lorcaserin 10 mg QD Placebo 80 % of patients Proportion of patients who lost 5% or 10% of body weight from baseline to week 52: Completers * * P <0.001, lorcaserin vs. placebo * * 0 5% wt loss 10% wt loss O Neil PM, et al. Obesity 20:1426, 2012
53 Lorcaserin, Change in Glycemic Parameters: BLOOM-DM A1C Fasting plasma glucose Change from baseline (%) * * * * * * * * Change from baseline mg/dl) * * ** * * * Study week Study week Lorcaserin 10 mg BID Lorcaserin 10 mg QD Placebo 50% Lorcaserin and 26% on placebo achieved A1C < 7.0% *P <0.001; **P <0.05 O Neil PM, et al. Obesity 20:1426, 2012
54 Newest FDA-Approved Weight Loss Drugs Agents Action Approval Bupropion/ Naltrexone Liraglutide Dopamine/NE reuptake inhibitor Opioid receptor antagonist GLP-1 receptor agonist June, 2014 Dec, 2014
55 Weight Loss in Patients with T2DM with Naltrexone-Bupropion Hollander P et al,. Diabetes Care 36:422, 2013
56 Effect of Naltrexone-Bupropion on Hb A1c in Patients with T2DM Hollander P et al,. Diabetes Care 36:422, 2013
57 GLP-1 Effects in Humans: Understanding the Metabolic Role of Incretins GLP-1 secreted upon the ingestion of food Promotes satiety and reduces appetite Alpha cells: Postprandial glucagon secretion Beta cells: Enhances glucosedependent insulin secretion Liver: Glucagon reduces hepatic glucose output Stomach: Helps regulate gastric emptying Adapted from Flint A, et al. J Clin Invest. 1998;101: ; Adapted from Larsson H, et al. Acta Physiol Scand. 1997;160: ; Adapted from Nauck MA, et al. Diabetologia. 1996;39: ; Adapted from Drucker DJ. Diabetes. 1998;47:
58 Liraglutide Approved for Diabetes Also Reduces Body Weight Weight Loss (kg) Screening Randomization Placebo 1.2 mg/d 1.8 mg/d 2.4 mg/d 3.0 mg/d Orlistat Weeks from Randomization Astrup A, et al. Lancet. 374:1606, 2009
59 Matching Medication to Patient When NOT TO USE: Lorcaserin Patient on a lot of SSRI and/or SNRI Orlistat GI disorders Phentermine/topiramate Pregnant-age women not on birth control Uncontrolled HTN Uncontrolled or active CVD Naltrexone/bupropion Suicidal ideation Uncontrolled HTN Liraglutide MCT at risk patients
60 Thomas EA et al, Obesity 24:37, 2016
61 Empagliflozin (EMPA-REG) Other BP Arterial stiffness Albuminuria Sympathetic nervous system activity Glucose Insulin Uric acid Weight Visceral adiposity Oxidative stress LDL-C HDL-C TG Adapted from Inzucchi SE et al. Diab Vasc Dis Res 12:90, 2015
62 Mingrone G et al, Lancet 386:964, 2015
63 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM: 5 Year Follow-up Primary Objective to assess 5 year outcomes from a randomized trial designed to compare surgery with conventional medical treatment for the treatment of T2DM in obese patients. n = 60 obese patients with T2DM Age years; BMI 35.0 kg/m 2 ; A1c 7.0% 5 years duration of T2DM 20 each assigned to Medical treatment Roux-en-Y gastric bypass 88% 5 year follow-up Biliopancreatic diversion Primary endpoint: A1c of 6.5% and FPG 5.6 mmol/l Mingrone G et al, Lancet 386:964, 2015
64 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM: Weight Mingrone G et al, Lancet 386:964, 2015
65 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM: Remission Rate Mingrone G et al, Lancet 386:964, 2015
66 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM: Metabolic Improvement Mingrone G et al, Lancet 386:964, 2015
67 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM:CVD Risk Mingrone G et al, Lancet 386:964, 2015
68 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM: Cardiovascular Drugs Mingrone G et al, Lancet 386:964, 2015
69 Bariatric-metabolic Surgery vs. Medical Treatment in Obese Patients with T2DM: HDL Cholesterol Mingrone G et al, Lancet 386:964, 2015
70 Change in HbA1c: Meta-Analysis of Surgical vs. Medical Trials
71 Summary and Conclusions In obese patients weight loss is difficult to achieve and more difficult to maintain. There is a strong metabolic basis for this. However, success can be achieved. In patients with T2DM Lifestyle has many benefits but not CVD event reduction Weight loss medications are effective but must be maintained and CVD benefits remain unproven Bariatric-metabolic surgery appears most effective in reducing A1c, but CVD?
72 Thank You!
The Reduced Obese State: The Challenge of Weight Maintenance 2011 Annual CAN Conference November 17, 2011
The Reduced Obese State: The Challenge of Weight Maintenance 2011 Annual CAN Conference November 17, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics Charles A. Boettcher
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
OBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
Management of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
New and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
Lorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, )
(World Health organization, WHO) 1996 WHO (Body mass index, BMI)2427 kg/m 2 27 kg/m 2 25% 30%2013-2014 43.5%(48.9%38.3%) (AACE/ACE)2016 1 BMI 27 kg/m 2 BMI 35 kg/m 2 (The Food and Drug Administration,
The New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
Management of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
Chief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
Overview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
Disclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014
Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity
Obesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH
Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA.
Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA Donna.Ryan@pbrc.edu National Summit on Health Disparities April 22, 2013 Disclosure Dr. Ryan has served as an advisor to Nutrisystem
Copyright 2017 by Sea Courses Inc.
Appetite Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
Obesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
ANGELA GINN-MEADOW RD LDN CDE
DIABETES DRUGS & TRENDS MADE SIMPLE PHARMD TO RD ANGELA GINN-MEADOW RD LDN CDE OBJECTIVES At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for
Appetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After
Appetite, Glycemia and Entero-Insular Hormone Responses Differ Between Oral, Gastric-Remnant and Duodenal Administration of a Mixed Meal Test After Roux-en-Y Gastric Bypass June 2018 How a surgical complication
COMBINATION OF PHENTERMINE/TOPIRAMATE ER AND LIRAGLUTIDE 3MG FOR INTENSIVE THERAPY OF SEVERE OBESITY & T2DM A CASE SERIES AND BRIEF REVIEW
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
Obesity Management in Type 2 Diabetes
Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe
For Asian individuals the BMI numbers are 27.5 and 25 respectively These values are from the NICE guidelines of 2014
Ken Cathcart DO FACE We need to define several things to start the talk Obesity is defined medically as a BMI of greater than 30 or a BMI >27 with co-morbidities such as hypertension, type 2 DM, dyslipidemia,
Non-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
Learning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
Obesity D R. A I S H A H A L I E K H Z A I M Y
Obesity D R. A I S H A H A L I E K H Z A I M Y Objectives Definition Pathogenesis of obesity Factors predisposing to obesity Complications of obesity Assessment and screening of obesity Management of obesity
Multiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
Professor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes
Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes Leigh Perreault, MD Associate Professor of Medicine Endocrinology, Metabolism and Diabetes University of Colorado Anschutz Medical
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
Pathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
OBESITY:Pharmacotherapy Vs Surgery
OBESITY:Pharmacotherapy Vs Surgery Dr. Ranajit Sen Chowdhury Associate Professor Department of Medicine Sir Salimullah Medical College & Mitford Hospital. 1 Historical Perspective Paleolithic Era > 25,000
Diabetes Risk Assessment and Treatment
Diabetes Risk Assessment and Treatment Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University Baltimore, Maryland, USA
Should Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
Understanding Obesity: The Causes, Effects, and Treatment Options
Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,
Early treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
Treatment of Severe Obesity
Treatment of Severe Obesity Louis J. Aronne, MD, FACP, FTOS, DABOM Sanford I Weill Professor of Metabolic Research Weill Cornell Medical College Comprehensive Weight Control Center Division of Endocrinology,
Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
Faculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
Why Do We Treat Obesity? Metabolic Complications
Why Do We Treat Obesity? Metabolic Complications 2 Metabolic Complications of Obesity Diabetes Risk 3 Criteria for Diagnosis of the Metabolic Syndrome Characteristic Waist circumference Triglycerides HDL-C
Neuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management. Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018 COI Faculty: Renuca Modi, MD, CCFP Diplomate of the
Diabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
Gut hormones KHATTAB
Gut hormones PROF:ABD ALHAFIZ HASSAN KHATTAB Gut as an endocrine gland The talk will cover the following : Historical background. Why this subject is chosen. Gastro-intestinal hormones and their function.
THE PERENNIAL STRUGGLE TO LOSE WEIGHT AND MAINTAIN: WHY IS IT SO DIFFICULT?
THE PERENNIAL STRUGGLE TO LOSE WEIGHT AND MAINTAIN: WHY IS IT SO DIFFICULT? Robert Ferraro, MD Medical Director Southwest Endocrinology Associates, PA Diabetes and Weight Management Center OBESITY The
Past, Present and Future of Pharmacotherapy for Obesity
Past, Present and Future of Pharmacotherapy for Obesity Dan Bessesen, MD Chief of Endocrinology; Denver Health Medical Center Professor of Medicine, University of Colorado School of Medicine Daniel.Bessesen@ucdenver.edu
The Physiology of Weight Regulation: Implications for Effective Clinical Care
Roundtable on Obesity Solutions The Physiology of Weight Regulation: Implications for Effective Clinical Care Lee M. Kaplan, MD, PhD Obesity, Metabolism & Nutrition Institute Massachusetts General Hospital
Lipids Carbohydrate Protein. Fatty Acids Glycerol. Mono/di-saccarides. Aminoacids. Fat Liver Muscle. Triglycerides Glycogen Protein
Lipids Carbohydrate Protein Fatty Acids Glycerol Mono/di-saccarides Fat Liver Muscle Aminoacids Triglycerides Glycogen Protein Microvascular Macrovascular Diabetes-specific Diabetes-enhanced HbA1c 5.7(6.0)
Disclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None
Disclosures None OBESITY Florencia Halperin, M.D. Medical Director, Program for Management Brigham and Women s Hospital Instructor in Medicine, Harvard Medical School Overview Obesity: Definition Definition
Update on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018
Update on the Recent Advances in Obesity Management Benjamin O Donnell, MD Oct 5 th, 2018 Objectives Background Control of Energy Homeostasis Approach to Diet and Exercise Medications Recently Approved
Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
Recent results of the research into the possible contribution of whey powders in the fight against obesity. David J Baer, PhD
Recent results of the research into the possible contribution of whey powders in the fight against obesity David J Baer, PhD Beltsville Human Nutrition Research Center Funded by USDA, ARS and the Whey
Chapter 24 Cholesterol, Energy Balance and Body Temperature. 10/28/13 MDufilho
Chapter 24 Cholesterol, Energy Balance and Body Temperature 10/28/13 MDufilho 1 Metabolic Role of the Liver Hepatocytes ~500 metabolic functions Process nearly every class of nutrient Play major role in
Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis
Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis Raja Chakraverty Assistant Professor in Pharmacology Bengal College of Pharmaceutical
Diabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
Anti-Obesity Drugs - Current Status & Application in Diabetic Patients - 순천향의대부천병원 내분비내과 김철희
Anti-Obesity Drugs - Current Status & Application in Diabetic Patients - 순천향의대부천병원 내분비내과 김철희 Obesity Treatment Pyramid BMI Surgery Pharmacotherapy Lifestyle Modification Diet Physical Activity Selecting
Syllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1:55-2:4pm Medical Management of Obesity: Lifestyle, Medicine, and Surgery SPEAKER Osama Hamdy, MD, PhD, FACE Disclosures The following relationships exist related to this presentation: Osama Hamdy, MD,
Bariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic Patients: 3-Year Outcomes
Bariatric Surgery vs. Intensive Medical Therapy in Obese Diabetic Patients: 3-Year Outcomes Results of the STAMPEDE Trial Philip R Schauer, Deepak L Bhatt, John P Kirwan, Kathy Wolski, Stacy A Brethauer,
Update on GLP-1 Past Present Future
Update on GLP-1 p Past Present Future Effects of GLP-1: Glucose Metabolism and Nutritional Balance L-Cells: Glp-1 release Betacellfollowing ingestion Stress Increases satiety reduces appetite Betacell-
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
Treating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
Diabesity: Treatment Options for an Epidemic of Growing Proportions
Diabesity: Treatment Options for an Epidemic of Growing Proportions www.freedigitalphotos.net Jennifer Poehls, MD Clinical Assistant Professor UW School of Medicine and Public Health Section of Endocrinology,
Diabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
Changing Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
The Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
The ABCDs of Obesity
The ABCDs of Obesity Adipose Based Chronic Disease Michael A. Bush, M.D. Clinical Chief, Division of Endocrinology Cedars-Sinai Medical Center Clinical Associate Professor, Geffen School of Medicine, UCLA
What s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
Overview of the Pharmacologic & Surgical Treatment for Obesity
Overview of the Pharmacologic & Surgical Treatment for Obesity Christopher D. Still, DO, FACN, FACP. FTOS Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research
Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
Innovate. Discover. Cure. Type 2 Diabetes what you and your family need to know
1 Innovate. Discover. Cure. Type 2 Diabetes what you and your family need to know Opening comments Steven R. Smith, MD Founding Scientific Director - TRI Professor, metabolic diseases program, Sanford-Burnham
SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
Pramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
Other Ways to Achieve Metabolic Control
Other Ways to Achieve Metabolic Control Nestor de la Cruz- Muñoz, MD, FACS Associate Professor of Clinical Surgery Chief, Division of Laparoendoscopic and Bariatric Surgery DeWitt Daughtry Family Department
For Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity
Role of glucagon-like peptide 1 receptor agonists in management of obesity Diana Isaacs, Pharm.D., BCPS, BC-ADM, CDE, Chicago State University, Chicago, IL, and Oak Lawn VA Clinic of Edward Hines Jr. VA
Therapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
CANA DAPA EMPA. Change in Baseline Body Weight (kg) *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg, EMPA=10 or 25 mg.
CANA DAPA EMPA Change in Baseline Body Weight (kg) 2 1 0-1 -2-3 -4-5 PBO SGLT2 inhibitor (low dose)* SGLT2 inhibitor (high dose)* *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg,
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest CLASSIFICATION OF OVERWEIGHT
Metabolic Syndrome in Asians
Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly
Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
New Insights into Mechanism of Action
Remission of Diabetes after Bariatric Surgery New Insights into Mechanism of Action Peng (Charles) Zhang, MD, PhD Shanghai Pudong Hospital Fudan University Pudong Medical Center March 20, 2015 Orlando,
Overweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University
Overweight and Obesity on the Menu Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University Prevention The most efficient and cost-effective approach
Comprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
Metabolic Syndrome. DOPE amines COGS 163
Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance
Managing Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity